Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05858320 · ClinicalTrials.gov registry record · Phase 3
The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients
A Phase 3 study of Heart Failure, sponsored by University of Michigan.
- Completed
- Registry status
- Phase 3
- Development phase
- 225
- Enrollment target
- 5
- Study locations
NCT05858320 is a Phase 3 study of Heart Failure that has completed, run by University of Michigan. The registered enrollment target is 225 participants, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 3 states.
The verdict
NCT05858320, a Phase 3 study of Heart Failure, has completed, sponsored by University of Michigan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 225 participants
- Enrollment target
- 5
- Study locations
Study Summary
The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the web application intervention or control in a 1:1 manner, stratified by site. The intervention is an adaptive medication optimization web application that extracts and analyzes the EHR data with a computable medication optimization algorithm. The algorithm provides a medication quality score and outputs medication optimization recommendations written in a patient -friendly manner.
Conditions Studied
Interventions
- OTHER SmartHF application
Study Locations (5)
Michigan
- University of Michigan - Ann Arbor
- Henry Ford Hospital and Health System - Detroit
- Trinity Healthcare St. Joseph Mercy Ann Arbor - Ypsilanti
Georgia
- Emory University, Grady Hospital - Atlanta
Missouri
- Washington University, Barns Jewish Hospital - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2023-07-21 |
| Est. Completion | 2025-12-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05858320
The ClinicalTrials.gov registry entry for NCT05858320 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,048-participant average among 397 other Heart Failure trials with a reported enrollment target (89% lower). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which SmartHF application is the first listed.
NCT05858320 reports 5 study locations spanning 3 distinct geographic areas - top geographies include Michigan, Georgia, Missouri.
Frequently Asked Questions
What is clinical trial NCT05858320 about?
NCT05858320 is a clinical study titled "The Impact of an Adaptive Patient-centered Web Application on Medication Optimization in HFrEF Patients". The SmartHF study is a 12-week prospective randomized controlled multicenter clinical trial. This study will investigate the efficacy of an adaptive web application to facilitate guideline-directed medical therapy (GDMT) optimization in HFrEF patients. Eligible participants will be randomized to the...
What is the current status of trial NCT05858320?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 225 participants. The study started on 2023-07-21. Estimated completion is 2025-12-01.
What conditions does trial NCT05858320 study?
This clinical trial studies the following conditions: Heart Failure.
What interventions are being tested in trial NCT05858320?
The interventions under investigation include: SmartHF application (OTHER).
Who is sponsoring clinical trial NCT05858320?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05858320 being conducted?
This trial has 5 study locations across Georgia, Michigan, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Home-based Cardiac Rehabilitation in Heart Failure
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone and SGLT2i in Combination in Hospitalized Patients with Heart Failure (CONFIRMATION-HF)
RECRUITING · Phase 3
-
A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart
RECRUITING · Phase 3
-
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
RECRUITING · Phase 3
-
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.